VOR Key Statistics, Chart & Performance
The current stock price of VOR is 11.64 USD. In the past month the price increased by 36.78%. In the past year, price decreased by -55.91%.
VOR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About VOR
Company Profile
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. The company is headquartered in Boston, Massachusetts and currently employs 159 full-time employees. The company went IPO on 2021-02-05. The firm is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.
Company Info
VOR BIOPHARMA INC
500 Boylston Street, Suite 1350
Boston MASSACHUSETTS US
Employees: 159
Phone: 16176556580
VOR BIOPHARMA INC / VOR FAQ
What does VOR do?
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. The company is headquartered in Boston, Massachusetts and currently employs 159 full-time employees. The company went IPO on 2021-02-05. The firm is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.
What is the current price of VOR stock?
The current stock price of VOR is 11.64 USD. The price decreased by -11.01% in the last trading session.
Does VOR BIOPHARMA INC pay dividends?
VOR does not pay a dividend.
How is the ChartMill rating for VOR BIOPHARMA INC?
VOR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists VOR stock?
VOR stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for VOR stock?
VOR BIOPHARMA INC (VOR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-61.13).
VOR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to VOR. When comparing the yearly performance of all stocks, VOR is a bad performer in the overall market: 96.49% of all stocks are doing better.
VOR Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to VOR. Both the profitability and financial health of VOR have multiple concerns.
VOR Financial Highlights
Over the last trailing twelve months VOR reported a non-GAAP Earnings per Share(EPS) of -61.13. The EPS decreased by -85.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1389.92% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
VOR Forecast & Estimates
9 analysts have analysed VOR and the average price target is 41.41 USD. This implies a price increase of 255.77% is expected in the next year compared to the current price of 11.64.